Literature DB >> 17728025

Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases.

Lynn W Kitchen1, David W Vaughn.   

Abstract

U.S. military physicians and researchers have collaborated in the development of eight U.S.-licensed vaccines since 1934, when product efficacy requirements were added to product safety requirements mandated in 1902. These vaccines include influenza (1945), rubella (1969), adenovirus types 4 and 7 (1980), meningococcus A, C, Y, W-135 (1981), hepatitis B (1981), oral typhoid (1989), Japanese encephalitis (1992), and hepatitis A (1995). Current efforts include new adenovirus and Japanese encephalitis vaccines, and vaccines to prevent dengue, diarrhea due to enterotoxigenic E. coli, Campylobacter, and Shigella, malaria, hemorrhagic fever with renal syndrome, scrub typhus, meningococcus type B, and HIV infection. All vaccines currently administered to U.S. military forces must be licensed by the U.S. Food and Drug Administration (FDA).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728025     DOI: 10.1016/j.vaccine.2007.07.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 2.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

3.  The relationship between mosquito abundance and rice field density in the Republic of Korea.

Authors:  Erin E Richards; Penny Masuoka; David Brett-Major; Matthew Smith; Terry A Klein; Heung Chul Kim; Assaf Anyamba; John Grieco
Journal:  Int J Health Geogr       Date:  2010-06-23       Impact factor: 3.918

4.  Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract.

Authors:  Emeline Goffin; Justine Javaux; Eric Destexhe; Carla D Pretto; Katherine R Spindler; Bénédicte Machiels; Laurent Gillet
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

Review 5.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

6.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

7.  Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.

Authors:  Irina Tretyakova; Igor S Lukashevich; Pamela Glass; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  Vaccine       Date:  2012-12-31       Impact factor: 3.641

8.  Seroconversion to Japanese Encephalitis Virus Among U.S. Infantry Forces in Korea.

Authors:  Angelia A Eick-Cost; Zheng Hu; Terry A Klein; Robert J Putnak; Richard G Jarman
Journal:  Am J Trop Med Hyg       Date:  2015-08-03       Impact factor: 2.345

Review 9.  The Global Emerging Infection Surveillance and Response System (GEIS), a U.S. government tool for improved global biosurveillance: a review of 2009.

Authors:  Kevin L Russell; Jennifer Rubenstein; Ronald L Burke; Kelly G Vest; Matthew C Johns; Jose L Sanchez; William Meyer; Mark M Fukuda; David L Blazes
Journal:  BMC Public Health       Date:  2011-03-04       Impact factor: 3.295

Review 10.  The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

Authors:  Silvia Ratto-Kim; In-Kyu Yoon; Robert M Paris; Jean-Louis Excler; Jerome H Kim; Robert J O'Connell
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.